Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine is an experimental small molecule compound belonging to the class of tetrahydroisoquinolines. It has a molecular formula of C17H19N3O2S and a molecular weight of approximately 329.42 g/mol. The compound is structurally characterized by a thienoxazepine core linked via an ether bond to a tetrahydroisoquinoline moiety. It has been studied as an inhibitor of nitric oxide synthase isoforms—specifically neuronal (NOS1), inducible (NOS2), and endothelial (NOS3) nitric oxide synthases—suggesting potential utility in modulating nitric oxide production for research or therapeutic purposes[5]. There are no known brand names or marketed formulations for this compound; it remains at the experimental stage.
- Other names
- (3R)-3-(1,2,3,4-Tetrahydroisoquinolin-7-yloxymethyl)-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine332 (ligand code)DB07007DB-07007DB 07007
02
Targets
NOS3 (eNOS)NOS2 (Nitric Oxide Synthase 2)NOS1 (nNOS)
Beyond the preview
Go deeper on (3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine.